Tag: Jazz Pharmaceuticals

The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan Diseases”

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsJazz Pharmaceuticals

Acceleware Ltd. Announces Closing of Shares for Debt Transactions

Providence St. Joseph Hospital Foundation Establishes First-Ever Endowed Chairs to Advance Excellence in Cardiac and Cancer Care

LungExpand Pro Gains 2025 Spotlight as Plant-Based Daily Support Formula Amid Rising Public Interest in Breathing Comfort and Respiratory Wellness

Tag: Jazz Pharmaceuticals

The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan Diseases”

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us